Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Laryngeal cancer
Stage/Subtype:  stage IV laryngeal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 80 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1216, NCI-2013-00500, NCT01810913
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-141, NCI-2014-01268, 2013-003622-86, NCT02105636
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-040, NCI-2014-02662, 2014-001749-26, NCT02252042
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719X2104, NCI-2013-00766, 2011-006017-34, NCT01602315
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, NCT01816984
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4981C00001, NCI-2014-01959, NCT02205333
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2104, NCI-2014-02359, 2014-000579-20, NCT02205398
A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 15309, NCI-2009-01492, NCT01044433
A Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13420, NCI-2012-01213, I4E-MC-JXBB, NCT01063075
Combination Chemotherapy with or without Erlotinib Hydrochloride in Treating Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0395, NCI-2011-03782, NCT01064479
Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13418, NCI-2012-01212, I4E-MC-JXBA, NCT01099358
Cetuximab Followed By Surgery and Chemoradiation Therapy in Treating Patients With Previously Untreated Stage III-IVA Head and Neck Squamous Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 08-013, NCI-2011-02479, NCT01218048
Cetuximab and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: UMCC 2009.009, NCI-2011-03619, HUM00027253, NCT01250522, NCT00904345
Docetaxel, Cisplatin, and Cetuximab in Treating Patients With Metastatic or Relapsed Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: ENT0033, NCI-2011-03271, 22329, SU-08222011-8290, NCT01437449
Chemotherapy and R-(-)-Gossypol Acetic Acid in Preserving the Larynx in Patients With Stage III or IV Laryngeal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HUM00043975, NCI-2012-01021, CR00040536, HUM 43975, UMCC 2010.101, NCT01633541
Start Over